Support group for mums from different ethnicities
Carolyn Nansubuga, a Cheltenham mother-of-four, attended several groups following the birth of her youngest child, now 20 months, but said she struggled as she "never had anything in common with the other mums".
Lives of Colour, a Gloucestershire-based race equity charity, will launch the Mothers of Colour group at Aspire Foundation, Cheltenham on Thursday, in partnership with the NHS perinatal maternity unit.
Florence Nyasamo, charity founder, said the partnership will allow the health needs of mothers from all ethnicities to be met.
More news stories for Gloucestershire
Listen to the latest news for Gloucestershire
National audit programme "Mothers and Babies: Reducing Risk through Audits, External" (MBRRACE-UK) found maternal deaths among black women were nearly three times higher compared with those of white women in 2020-22.
The Mothers of Colour group will cover newborn care, mental wellness, and maternal health.
Ms Nansubuga said, at the sessions, she hopes to meet mothers who "understand the cultural nuances" she experiences after not "fitting in" previously.
"Groups are meant to give you rest from the mundane things of motherhood you've been going through at home so, when you go there, you have to feel welcome," she said.
"But it's not just me, even my baby would think 'I don't look like everybody else here'.
"When I heard about this group starting up I was super excited because, finally, we have the chance to attend a baby group and be ourselves."
Ms Nyasamo said it can be hard for women who have moved from another country to understand the "small nuances" at groups in the UK.
"It's nice to go into a space where you can just be," she said.
"We know with the NHS partnership, if we need a midwife or health visitor to come and have a conversation, then we've already got those connections.
"Whatever the women will ask for, we'll do our best to make sure their needs are met."
Mothers of Colour is open to women of all ethnicities.
Follow BBC Gloucestershire on Facebook, X and Instagram. Send your story ideas to us on email or via WhatsApp on 0800 313 4630.
Postnatal support group set up for black mothers
Letter scheme aims to give voice to black mums
Maternity care for black women must improve - MP
Lives of Colour
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
6 insect bites and stings to watch out for
With temperatures soaring over the past few weeks, many of us have been spending more time outdoors, making the most of the warm weather. But while barbecues and picnics are summer highlights, all that fresh air can sometimes come with unwanted side effects – insect bites. Most insect bites are harmless and will clear up within a few days, according to the NHS, but some can trigger allergic reactions, infections or – in rare cases – more serious complications. From ticks to horseflies, here's what you need to know about the bites to watch out for – and when it's time to get medical help. Ticks are small, spider-like creatures that live in grassy areas and woodland and feed on the blood of animals and people. It doesn't hurt when a tick bites you, so you might not realise you've been bitten until you find one attached to your skin. The biggest concern with tick bites is Lyme disease. The UK Health Security Agency (UKHSA) estimates between 4% and 10% of ticks in the UK carry this bacterial infection, which can lead to flu-like symptoms, fatigue and, in some cases, serious long-term complications like arthritis and nerve problems. If you're bitten by a tick, you should remove it as soon as you see it. How to treat: To remove the tick safely, use fine-tipped tweezers to grasp it as close to the skin as possible Pull upwards slowly without twisting or crushing it Wash the area with soap and water Keep the tick in a container to show your GP if needed Never burn the tick off or cover it with chemicals, as this can increase infection When to see a doctor: A circular rash that looks like a bullseye around a tick bite can be an early symptom of Lyme disease. This usually appears within one to four weeks of being bitten, according to the NHS. If you notice a rash or feel unwell after a tick bite, contact your GP straight away. Horseflies are large, dark flies with powerful mouthparts that saw into the skin. Only female horseflies bite but the bite can be painful and quickly causes redness, swelling and itchiness. In some cases, horsefly bites can lead to fluid-filled blisters or infection. How to treat: Wash the area and apply antiseptic Cover up with clothing if you're near fields Horseflies are attracted to dark colours, so opt for light clothing Use insect repellent that specifically mentions horseflies on the label When to see a doctor: If the bite becomes increasingly swollen, warm or oozes pus, speak to a pharmacist or GP as you may need antibiotics. Most bee or wasp stings cause redness and pain, but in rare cases they can trigger a severe allergic reaction called anaphylaxis. Hornet stings are similar but can be more painful because hornets inject more venom. Unlike bees, hornets and wasps can sting repeatedly. How to treat: Remove the sting if visible by scraping sideways with a credit card Wash with soap and water Apply a cold compress for swelling Take painkillers if needed When to see a doctor: Call 999 or got to A&E straight away if you have difficulty breathing, dizziness or swelling in your face or throat, or you develop a rash that spreads rapidly. While UK mosquitos generally don't transmit diseases like malaria (the risk is currently very low), their bites can still cause red, itchy bumps that sometimes blister. Children can react more strongly, developing large, inflamed areas. How to treat: Use a cold compress to reduce swelling Apply an antihistamine cream or take an antihistamine tablet Avoid scratching to lower the risk of infection Wear long sleeves and trousers if mosquitos are about Avoid scented products that can attract them. When to see a doctor: Most bites and stings improve within a few days, but you should get medical help if You were bitten near your eyes, throat or mouth, the swelling is severe or spreading rapidly, you have symptoms of infection (redness, pus, warmth) or if you feel dizzy or nauseous. If you or someone else develops severe symptoms of an allergic reaction, like difficulty breathing, tight chest or swelling in the mouth or throat, call 999 immediately. Harvest mites are tiny red or orange mites that are most active in late summer and early autumn. Their bites often appear as clusters of small, intensely itchy red bumps, typically around the ankles, waistline or under tight clothing. Most bites are harmless, but severe reactions can occur if they become infected through scratching. How to treat: Wash skin with soap and water Apply cold compresses to reduce itching Use an antiseptic cream to lower infection risk When to see a doctor: If the bites become swollen, ooze pus, or you feel generally unwell, speak to your GP. Red ants (including flying red ants) can bite or sting, releasing formic acid that causes a sharp, burning pain and local swelling. While most reactions are mild, some people develop large areas of redness and swelling that last days, and rarely, a severe allergic reaction. How to treat: Wash the area with soap and water. Apply a cold pack for 20 minutes. Take an antihistamine if it's very itchy. When to see a doctor: Call 999 or go to A&E if you have trouble breathing, feel faint or develop swelling in your mouth or throat. Read more about insects: The truth about flying ant day and the best way to get rid of the pesky insects (Yahoo Life UK, 4-min read) If you've been bitten by a tick, follow these 5 steps (Yahoo Life UK, 5-min read) Not All Garden Bugs Are Bad—Here's a Guide to the Insects That Actually Benefit Your Plants (RealSimple, 4-min read)
Associated Press
an hour ago
- Associated Press
Plexāā Closes $4.5 Million Funding Extension to Drive U.S. Launch of BLOOM43 Platform for Breast Surgery
LONDON--(BUSINESS WIRE)--Jul 8, 2025-- Plexāā, a MedTech startup behind the award-winning BLOOM 43 medical device for breast surgery, has announced the close of a $4.5 million funding extension round. The strategic capital infusion will support the imminent U.S. launch of BLOOM 43, while also laying the groundwork for future innovations. The funding also strengthens the company's position ahead of their planned Series A fundraising round. Complication rates in breast surgeries, which can include infection, skin necrosis and the need for additional surgeries, have been recorded as high as 30 percent. 1 BLOOM 43 is the world's first fully wearable medical device designed to help patients prepare for breast cancer surgery and reconstruction by harnessing the power of Supraphysiological Preconditioning ™. The new technique safely and intermittently thermally preconditions the skin causing the release of heat-shock proteins that cause vasodilation and increased blood flow to the area. This process has been shown to reduce wound healing complications in proof-of-concept clinical trials. Along with its BLOOM 43 companion app, the device has demonstrated substantial improvements in the patient experience and surgical readiness, harnessing the power of holistic Prehabilitation ™ and preconditioning. The company has already secured multiple partners for its upcoming U.S. commercial launch. 'I want to thank our team for the tremendous progress it has made to make this financing possible,' said Dr. Saahil Mehta, founder and CEO of Plexāā. 'Securing this funding validates confidence in our flagship technology and the concept of Supraphysiological Preconditioning ™, and it energizes the team as we prepare to bring BLOOM 43 to a wider patient population in the U.S. and beyond. The funds will support this pivotal launch and market expansion, as well as the exciting development of our technology platform – including devices and apps targeting additional surgical specialties and creating a whole new category in surgery.' Plexāā Ltd has been backed by TCP Health Ventures (the dedicated healthcare investment arm of The Capital Partnership group of companies) who led the Seed Round. This extension round comprises existing and new investors including TCP. Further investment includes over $1.6 million in i4i grant funding from the National Institute for Health and Care Research (NIHR), and $1.3 million from Thena Capital, a London-based VC firm backed by the British Business Bank and focused on digital health and fast-tracked Medtech. Tatum Getty, founding General Partner at THENA Capital added, 'Since 2023, we've been closely tracking Plexāā's progress and the development of its first device, BLOOM 43. We couldn't be more excited for Plexāā to become our first portfolio company for THENA Capital's Fund I. The company is solving a critical and under-addressed challenge across the surgical pathway- reducing post-operative complications for patients which also addresses the impact to both providers and payers. 'Saahil and his team bring together clinical, engineering, and operational expertise from some of the UK's leading institutions. Their bold ambition to scale globally, beginning with an imminent commercial launch in the U.S., is exactly the kind of UK MedTech leadership team we look to champion. Our fund's commercialisation support model is well-suited to help Plexāā expand into women's health and adjacent categories where better outcomes and patient experiences are urgently needed.' Plexāā plans to collaborate with clinicians, patients, and partners worldwide to make prehabilitation and preconditioning the standard of care for surgery — and to deliver transformative solutions that address unmet needs in surgical care. About Plexāā Plexāā is a pioneering UK-based MedTech company focused on improving surgical outcomes through devices and digital products. Its flagship device, BLOOM 43, enables patients to supraphysiologically precondition their skin, potentially reducing the risk of wound healing complications such as infection and skin necrosis, which affect one in three women undergoing breast surgery. Plexāā is also exploring the application of this technology in other surgical fields, including obstetrics for C-sections, orthopaedics for joint operations, and general and vascular surgery, with a commitment to improving pre-operative preparation for surgery and patient outcomes. About TCP Health Ventures TCP Health Ventures is the dedicated healthcare investment arm of The Capital Partnership group of companies, a multi-asset investment company with assets under management of $7 billion. Headquartered out of London, TCP Health Ventures manages assets of $ 225 million across 15+ investments in the med-tech space and has a med-tech investing experience of 10 years. About the NIHR The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by: NIHR is funded by the Department of Health and Social Care. Its work in low- and middle- income countries is principally funded through UK international development funding from the UK government. About THENA Capital THENA Capital is a London-based venture capital firm backing the world's next category-defining medical technologies. We invest in breakthrough companies transforming care experiences through digital health, fast-tracked medical devices, and clinical-grade innovation. THENA's debut Fund 1, focuses on high-impact, UK-founded technologies addressing unmet needs across women's health, oncology, cardiovascular disease, chronic conditions, and care delivery. With deep clinical, regulatory and operational expertise, THENA Capital partners with founders to unlock international scale, navigate complex markets, and build enduring category leaders in global healthcare. References 1 Annals of Translational Medicine, Dec 2023, Management of complications following implant-based breast reconstruction: a narrative review, Dean H. Meshkin 1^, Joseph M. Firriolo 1, Nolan S. Karp 2, Ara A. Salibian 1 View source version on CONTACT: Media Contacts: Sam Choinski Pazanga Health Communications [email protected] (860) 301-5058 [email protected] KEYWORD: EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA NEW YORK INDUSTRY KEYWORD: TECHNOLOGY BIOTECHNOLOGY HEALTH CONSUMER APPS/APPLICATIONS SURGERY PROFESSIONAL SERVICES ONCOLOGY MEDICAL DEVICES SOFTWARE DATA ANALYTICS HEALTH TECHNOLOGY WOMEN DATA MANAGEMENT SOURCE: Plexāā Copyright Business Wire 2025. PUB: 07/08/2025 03:46 PM/DISC: 07/08/2025 03:46 PM
Business Wire
an hour ago
- Business Wire
Eluciderm, Inc. Announces U.S. FDA Clearance of IND Application for ELU42
SAN DIEGO--(BUSINESS WIRE)--Eluciderm, Inc., a clinical-stage pharmaceutical company developing small molecule therapeutics designed to promote healing and regenerative repair of injured tissue, announced today that on June 30, 2025 the company received clearance from the U.S. Food & Drug Administration (FDA) for its Investigational New Drug (IND), ELU42, for a Phase 1/2a open-label study evaluating safety and efficacy in patients with diabetic foot ulcers (DFUs). ELU42 is a novel, topical, small molecule Wnt modulator with bacteriostatic properties for the treatment of chronic open wounds. 'The FDA's IND clearance of ELU42 marks an exciting transition for Eluciderm from preclinical research to full clinical-stage company,' said Daniel D. Holsworth, PhD, Chief Executive Officer of Eluciderm. Share 'The FDA's IND clearance of ELU42 marks an exciting transition for Eluciderm from preclinical research to full clinical-stage company,' said Daniel D. Holsworth, PhD, Chief Executive Officer of Eluciderm. 'ELU42 is the first in our pipeline of Wnt signaling modulators developed around a novel mechanistic approach to tissue healing and repair that we believe will shift the paradigm from simply managing patients' wounds to truly healing them.' The ELU42 Phase 1/2a trial is an open-label study evaluating the topical spray for safety and efficacy in a cohort of 15 patients with diabetic foot ulcers (DFUs). The study is set to begin the first week of August 2025 at three U.S. sites and will assess multiple clinical endpoints, including wound area reduction, closure rates, and safety metrics. The data from this trial will establish the foundation of a Phase 2 clinical trial in 2026, with strong potential for a Breakthrough Therapy designation in early 2027. 'This first-in-human trial is a defining moment for Eluciderm. ELU42 has the potential to change the standard of care for patients worldwide who suffer from non-healing wounds and underscores our commitment to transforming wound care,' said John P. Delgado, MD, Chief Medical Officer of Eluciderm. 'We believe everyone can be a SuperHealer TM.' About Eluciderm, Inc. Eluciderm is a San Diego-based clinical-stage pharmaceutical company pioneering topical small-molecule therapies that awaken the body's innate healing capacity. The company's approach is grounded in a targeted mechanism of action that selectively modulates the Wnt signaling pathway, with the goal of redefining wound healing and clinical outcomes. Eluciderm's platform, anchored by ELU42, includes therapeutics designed to promote healing and regenerative repair of a wide variety of wound injuries, including those from third-degree burns, surgical incisions, elastic cartilage reconstructions, pulmonary fibrotic damage from environmental factors, and inflammatory skin diseases. Based on favorable data from the National Cancer Institute's NCI-60 screening program, Eluciderm is also in the early stages of investigating oncological applications of their mechanistic methodology. For more information, visit and follow Eluciderm on LinkedIn. Forward-Looking Statements This press release may contain 'forward-looking statements' within the meaning of the United States Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the initiation, timing, and progress of clinical trials; the potential therapeutic benefits of ELU42; and the development plans for Eluciderm, Inc.'s pipeline. These forward-looking statements are based on current expectations and beliefs and are subject to a number of risks and uncertainties, including those related to clinical development, regulatory approvals, manufacturing, and commercialization. Actual results may differ materially from those expressed or implied in the forward-looking statements. Eluciderm, Inc. disclaims any obligation to update these statements except as required by law.
